11,141 Shares in Arcus Biosciences, Inc. (NYSE:RCUS) Bought by NEOS Investment Management LLC

NEOS Investment Management LLC purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUSFree Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,141 shares of the company’s stock, valued at approximately $213,000.

A number of other hedge funds have also bought and sold shares of the business. FMR LLC grew its position in shares of Arcus Biosciences by 4.9% in the third quarter. FMR LLC now owns 4,780,052 shares of the company’s stock valued at $85,802,000 after purchasing an additional 222,280 shares in the last quarter. Vanguard Group Inc. grew its position in Arcus Biosciences by 1.4% during the third quarter. Vanguard Group Inc. now owns 4,493,818 shares of the company’s stock worth $80,664,000 after buying an additional 61,040 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Arcus Biosciences by 11.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,594,609 shares of the company’s stock worth $30,459,000 after buying an additional 158,094 shares in the last quarter. Decheng Capital LLC purchased a new position in Arcus Biosciences during the fourth quarter worth about $16,613,000. Finally, Charles Schwab Investment Management Inc. grew its position in Arcus Biosciences by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,182 shares of the company’s stock worth $9,019,000 after buying an additional 11,341 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, COO Jennifer Jarrett sold 11,551 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the transaction, the chief operating officer now owns 215,253 shares of the company’s stock, valued at approximately $3,777,690.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 12.30% of the stock is currently owned by corporate insiders.

Arcus Biosciences Price Performance

NYSE RCUS opened at $15.50 on Friday. Arcus Biosciences, Inc. has a 1-year low of $12.95 and a 1-year high of $25.47. The stock has a 50-day moving average of $16.25 and a 200-day moving average of $16.75.

Arcus Biosciences (NYSE:RCUSGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.92. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $28.77 million. Arcus Biosciences had a negative return on equity of 40.98% and a negative net margin of 97.47%. Arcus Biosciences’s revenue for the quarter was up 480.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.09) EPS. As a group, equities research analysts forecast that Arcus Biosciences, Inc. will post -3.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on RCUS. Truist Financial restated a “buy” rating and set a $50.00 target price on shares of Arcus Biosciences in a research report on Monday, March 25th. Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a research report on Thursday, May 9th. Finally, Citigroup upped their price objective on Arcus Biosciences from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.50.

View Our Latest Research Report on RCUS

About Arcus Biosciences

(Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Featured Stories

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.